Design, synthesis, and evaluation of novel imidazo[1,2- a ][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity

Journal of Medicinal Chemistry

Volumn 58, Issue 1, 2015, Pages 237-251

  Dao, Pascal ^a   Smith, Nikaia ^a   Tomkiewicz Raulet, Céline ^b   Yen Pon, Expédite ^a   Camacho Artacho, Marta ^c   Lietha, Daniel ^c   Herbeuval, Jean Phillipe ^a   Coumoul, Xavier ^b   Garbay, Christiane ^a   Chen, Huixiong ^a,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c Structural Biology and Biocomputing Programme   (Spain)

^d GUANGDONG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITROBENZYL) N (3,4,5 TRIMETHOXYPHENYL)IMIDAZO[1,2 A][1,3,5]TRIAZIN 2 AMINE; 2 [2 (2 METHOXY 4 MORPHOLINOPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]BENZOATE; 2 [2 (4 CYANOPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO] N METHYLBENZAMIDE; 2 [4 (2 METHOXY 4 MORPHOLINOPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]BENZOATE; 2 [4 (4 CYANOPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO] N METHYLBENZAMIDE; 2 [4 AMINO 6 (4 CYANOPHENYLAMINO) 1,3,5 TRIAZIN 2 YLAMINO]METHYLBENZAMIDE; 4 (2 NITROBENZYL) N (3,4,5 TRIMETHOXYPHENYL)IMIDAZO[1,2 A][1,3,5]TRIAZIN 2 AMINE; CYTOTOXIC AGENT; FOCAL ADHESION KINASE INHIBITOR; METHYL 2 [2 (2 METHOXY 4 MORPHOLINOPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]BENZOATE; METHYL 2 [2 (3,4,5 TRIMETHOXYPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]BENZOATE; METHYL 2 [4 (2 METHOXY 4 MORPHOLINOPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]BENZOATE; METHYL 2 [4 AMINO 6 (2 METHOXY 4 MORPHOLINOPHENYLAMINO) 1,3,5 TRIAZIN 2 YLAMINO]BENZOATE; METHYL 2 [4 AMINO 6 [4 [(BENZYLOXYCARBONYLAMINO)METHYL]PHENYLAMINO] 1,3,5 TRIAZIN 2 YLAMINO]BENZOATE; METHYL 2 [[2 (3,4,5 TRIMETHOXYPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YL]METHYL]BENZOATE; METHYL 2 [[2 [[4 [[[(VINYLOXY)CARBONYL]AMINO]METHYL]PHENYL]AMINO]IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YL]AMINO]BENZOATE; METHYL 2 [[4 (3,4,5 TRIMETHOXYPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YL]METHYL]BENZOATE; METHYL 2 [[4 [[4 [[[(VINYLOXY)CARBONYL]AMINO]METHYL]PHENYL]AMINO]IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YL]AMINO]BENZOATE; METHYL 3 [2 (3,4,5 TRIMETHOXYPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]BENZOATE; METHYL 3 [4 (3,4,5 TRIMETHOXYPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]BENZOATE; METHYL 3 [4 AMINO 6 (3,4,5 TRIMETHOXYPHENYLAMINO) 1,3,5 TRIAZIN 2 YLAMINO]BENZOATE; N 2 [2 (4 CYANOPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]PHENYL]METHANESULFONAMIDE; N 2 [4 (4 CYANOPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]PHENYL]METHANESULFONAMIDE; N METHYL 2 [2 (3,4,5 TRIMETHOXYPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]BENZOATE; N METHYL 2 [4 (3,4,5 TRIMETHOXYPHENYLAMINO)IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]BENZOATE; N [2 [4 AMINO 6 (4 CYANOPHENYLAMINO) 1,3,5 TRIAZIN 2 YLAMINO]PHENYL]METHANESULFONAMIDE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINYL 4 [[2 [[2 (METHYLCARBAMOYL)PHENYL]AMINOIMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]BENZOATE; VINYL 4 [[4 [[2 (METHYLCARBAMOYL)PHENYL]AMINO]IMIDAZO[1,2 A][1,3,5]TRIAZIN 4 YLAMINO]BENZOATE; ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; IMIDAZOLE DERIVATIVE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL CYCLE PROGRESSION; CELL MIGRATION; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; G2 PHASE CELL CYCLE CHECKPOINT; HCT116 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; CELL ADHESION; CELL MOTION; CELL SURVIVAL; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FOCAL ADHESION PROTEIN-TYROSINE KINASES; G2 PHASE CELL CYCLE CHECKPOINTS; HCT116 CELLS; HUMANS; IMIDAZOLES; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; TRIAZINES;

EID: 84920842311     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500784e     Document Type: Article

References (41)

1. Zhang, J.; Hochwald, S. N. The Role of FAK in Tumor Metabolism and Therapy Pharmacol. Ther. 2014, 142, 154-163
2. Cance, W. G.; Kurenova, E.; Marlowe, T.; Golubovskaya, V. Disrupting the Scaffold to Improve Focal Adhesion Kinase-Targeted Cancer Therapeutics Sci. Signaling 2013, 6 pe10
3. Lechertier, T.; Hodivala-Dilke, K. Focal Adhesion Kinase and Tumour Angiogenesis J. Pathol. 2012, 226, 404-412
4. Ma, W. W. Development of Focal Adhesion Kinase Inhibitors in Cancer Therapy Anticancer Agents Med. Chem. 2011, 11, 638-642
5. Golubovskaya, V. M.; Zheng, M.; Zhang, L.; Li, J.-L.; Cance, W. G. The Direct Effect of Focal Adhesion Kinase (FAK), Dominant-Negative FAK, FAK-CD and FAK siRNA on Gene Expression and Human MCF-7 Breast Cancer Cell Tumorigenesis BMC Cancer 2009, 9 280
6. Xu, L. H.; Owens, L. V.; Sturge, G. C.; Yang, X.; Liu, E. T.; Craven, R. J.; Cance, W. G. Attenuation of the Expression of the Focal Adhesion Kinase Induces Apoptosis in Tumor Cells Cell Growth Differ. 1996, 7, 413-418
7. Hauck, C. R.; Sieg, D. J.; Hsia, D. A.; Loftus, J. C.; Gaarde, W. A.; Monia, B. P.; Schlaepfer, D. D. Inhibition of Focal Adhesion Kinase Expression or Activity Disrupts Epidermal Growth Factor-Stimulated Signaling Promoting the Migration of Invasive Human Carcinoma Cells Cancer Res. 2001, 61, 7079-7090
8. McLean, G. W.; Brown, K.; Arbuckle, M. I.; Wyke, A. W.; Pikkarainen, T.; Ruoslahti, E.; Frame, M. C. Decreased Focal Adhesion Kinase Suppresses Papilloma Formation during Experimental Mouse Skin Carcinogenesis Cancer Res. 2001, 61, 8385-8389
9. Parsons, J. T.; Slack-Davis, J.; Tilghman, R.; Roberts, W. G. Focal Adhesion Kinase: Targeting Adhesion Signaling Pathways for Therapeutic Intervention Clin. Cancer Res. 2008, 14, 627-632
10. Shen, T.-L.; Park, A. Y.-J.; Alcaraz, A.; Peng, X.; Jang, I.; Koni, P.; Flavell, R. A.; Gu, H.; Guan, J.-L. Conditional Knockout of Focal Adhesion Kinase in Endothelial Cells Reveals Its Role in Angiogenesis and Vascular Development in Late Embryogenesis J. Cell Biol. 2005, 169, 941-952
11. Weis, S. M.; Cheresh, D. A. Pathophysiological Consequences of VEGF-Induced Vascular Permeability Nature 2005, 437, 497-504
12. Duffy, M. J. The Urokinase Plasminogen Activator System: Role in Malignancy Curr. Pharm. Des. 2004, 10, 39-49
13. Braren, R.; Hu, H.; Kim, Y. H.; Beggs, H. E.; Reichardt, L. F.; Wang, R. Endothelial FAK Is Essential for Vascular Network Stability, Cell Survival, and Lamellipodial Formation J. Cell Biol. 2006, 172, 151-162
14. Peng, X.; Ueda, H.; Zhou, H.; Stokol, T.; Shen, T.-L.; Alcaraz, A.; Nagy, T.; Vassalli, J.-D.; Guan, J.-L. Overexpression of Focal Adhesion Kinase in Vascular Endothelial Cells Promotes Angiogenesis in Transgenic Mice Cardiovasc. Res. 2004, 64, 421-430
15. Tavora, B.; Batista, S.; Reynolds, L. E.; Jadeja, S.; Robinson, S.; Kostourou, V.; Hart, I.; Fruttiger, M.; Parsons, M.; Hodivala-Dilke, K. M. Endothelial FAK Is Required for Tumour Angiogenesis EMBO Mol. Med. 2010, 2, 516-528
16. Huang, Y.; Zhang, S. [Focal adhesion kinase expression and angiogenesis in breast carcinoma] Nan Fang Yi Ke Da Xue Xue Bao 2007, 27, 1370-1373
17. Halder, J.; Lin, Y. G.; Merritt, W. M.; Spannuth, W. A.; Nick, A. M.; Honda, T.; Kamat, A. A.; Han, L. Y.; Kim, T. J.; Lu, C.; Tari, A. M.; Bornmann, W.; Fernandez, A.; Lopez-Berestein, G.; Sood, A. K. Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma Cancer Res. 2007, 67, 10976-10983
18. Dao, P.; Jarray, R.; Le Coq, J.; Lietha, D.; Loukaci, A.; Lepelletier, Y.; Hadj-Slimane, R.; Garbay, C.; Raynaud, F.; Chen, H. Synthesis of Novel Diarylamino-1,3,5-Triazine Derivatives as FAK Inhibitors with Anti-Angiogenic Activity Bioorg. Med. Chem. Lett. 2013, 23, 4552-4556
19. Dao, P.; Jarray, R.; Smith, N.; Lepelletier, Y.; Coq, J. L.; Lietha, D.; Hadj-Slimane, R.; Herbeuval, J.-P.; Garbay, C.; Raynaud, F.; Chen, H. Inhibition of Both Focal Adhesion Kinase and Fibroblast Growth Factor Receptor 2 Pathways Induces Anti-Tumor and Anti-Angiogenic Activities Cancer Lett. 2014, 348, 88-99
20. Golubovskaya, V. M. A Small Molecule Inhibitor, 1,2,4,5-Benzenetetraamine Tetrahydrochloride, Targeting the Y397 Site of Focal Adhesion Kinase Decreases Tumor Growth J. Med. Chem. 2008, 51, 7405-7416
21. Roberts, W. G. Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271 Cancer Res. 2008, 68, 1935-1944
22. Sakurama, K.; Noma, K.; Takaoka, M.; Tomono, Y.; Watanabe, N.; Hatakeyama, S.; Ohmori, O.; Hirota, S.; Motoki, T.; Shirakawa, Y.; Yamatsuji, T.; Haisa, M.; Matsuoka, J.; Tanaka, N.; Naomoto, Y. Inhibition of Focal Adhesion Kinase as a Potential Therapeutic Strategy for Imatinib-Resistant Gastrointestinal Stromal Tumor Mol. Cancer Ther. 2009, 8, 127-134
23. Lietha, D.; Eck, M. J. Crystal Structures of the FAK Kinase in Complex with TAE226 and Related Bis-Anilino Pyrimidine Inhibitors Reveal a Helical DFG Conformation PLoS One 2008, 3 e3800
24. Shi, Q.; Hjelmeland, A. B.; Keir, S. T.; Song, L.; Wickman, S.; Jackson, D.; Ohmori, O.; Bigner, D. D.; Friedman, H. S.; Rich, J. N. A Novel Low-Molecular Weight Inhibitor of Focal Adhesion Kinase, TAE226, Inhibits Glioma Growth Mol. Carcinog. 2007, 46, 488-496
25. Watanabe, N.; Takaoka, M.; Sakurama, K.; Tomono, Y.; Hatakeyama, S.; Ohmori, O.; Motoki, T.; Shirakawa, Y.; Yamatsuji, T.; Haisa, M.; Matsuoka, J.; Beer, D. G.; Nagatsuka, H.; Tanaka, N.; Naomoto, Y. Dual Tyrosine Kinase Inhibitor for Focal Adhesion Kinase and Insulin-like Growth Factor-I Receptor Exhibits Anticancer Effect in Esophageal Adenocarcinoma in Vitro and in Vivo Clin. Cancer Res. 2008, 14, 4631-4639
26. Kurio, N.; Shimo, T.; Fukazawa, T.; Takaoka, M.; Okui, T.; Hassan, N. M. M.; Honami, T.; Hatakeyama, S.; Ikeda, M.; Naomoto, Y.; Sasaki, A. Anti-Tumor Effect in Human Breast Cancer by TAE226, a Dual Inhibitor for FAK and IGF-IR in Vitro and in Vivo Exp. Cell Res. 2011, 317, 1134-1146
27. Liu, T.-J.; LaFortune, T.; Honda, T.; Ohmori, O.; Hatakeyama, S.; Meyer, T.; Jackson, D.; de Groot, J.; Yung, W. K. A. Inhibition of Both Focal Adhesion Kinase and Insulin-like Growth Factor-I Receptor Kinase Suppresses Glioma Proliferation in Vitro and in Vivo Mol. Cancer Ther. 2007, 6, 1357-1367
28. Heinrich, T.; Seenisamy, J.; Emmanuvel, L.; Kulkarni, S. S.; Bomke, J.; Rohdich, F.; Greiner, H.; Esdar, C.; Krier, M.; Grädler, U.; Musil, D. Fragment-Based Discovery of New Highly Substituted 1 H -Pyrrolo[2,3- b ]- and 3 H -Imidazolo[4,5- b ]-pyridines as Focal Adhesion Kinase Inhibitors J. Med. Chem. 2013, 56, 1160-1170
29. Dao, P.; Garbay, C.; Chen, H. Regioselective Synthesis of imidazo[1,2-a][1,3,5]triazines and 3,4-dihydroimidazo[1,2-a][1,3,5]triazines from [1,3,5]triazin-2,4-Diamines Tetrahedron 2013, 69, 3867-3871
30. Lev, S.; Moreno, H.; Martinez, R.; Canoll, P.; Peles, E.; Musacchio, J. M.; Plowman, G. D.; Rudy, B.; Schlessinger, J. Protein Tyrosine Kinase PYK2 Involved in Ca(2+)-Induced Regulation of Ion Channel and MAP Kinase Functions Nature 1995, 376, 737-745
31. Kath, J. C.; Luzzio, M. J. Composes Pour Traiter Le Developpement Anormal de Cellules. International Patent WO2004056786 A2, July 8, 2004.
32. Slack-Davis, J. K.; Martin, K. H.; Tilghman, R. W.; Iwanicki, M.; Ung, E. J.; Autry, C.; Luzzio, M. J.; Cooper, B.; Kath, J. C.; Roberts, W. G.; Parsons, J. T. Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor J. Biol. Chem. 2007, 282, 14845-14852
33. Gabarra-Niecko, V.; Schaller, M. D.; Dunty, J. M. FAK Regulates Biological Processes Important for the Pathogenesis of Cancer Cancer Metastasis Rev. 2003, 22, 359-374
34. Romer, L. H.; McLean, N.; Turner, C. E.; Burridge, K. Tyrosine Kinase Activity, Cytoskeletal Organization, and Motility in Human Vascular Endothelial Cells Mol. Biol. Cell 1994, 5, 349-361
35. Gates, R. E.; King, L. E., Jr.; Hanks, S. K.; Nanney, L. B. Potential Role for Focal Adhesion Kinase in Migrating and Proliferating Keratinocytes near Epidermal Wounds and in Culture Cell Growth Differ. 1994, 5, 891-899
36. Taylor, J. M.; Mack, C. P.; Nolan, K.; Regan, C. P.; Owens, G. K.; Parsons, J. T. Selective Expression of an Endogenous Inhibitor of FAK Regulates Proliferation and Migration of Vascular Smooth Muscle Cells Mol. Cell. Biol. 2001, 21, 1565-1572
37. Ilic, D. Reduced Cell Motility and Enhanced Focal Adhesion Contact Formation in Cells from FAK-Deficient Mice Nature 1995, 377, 539-544
38. Brábek, J.; Mierke, C. T.; Rösel, D.; Veselý, P.; Fabry, B. The Role of the Tissue Microenvironment in the Regulation of Cancer Cell Motility and Invasion Cell Commun. Signaling 2010, 8 22
39. Beningo, K. A.; Dembo, M.; Kaverina, I.; Small, J. V.; Wang, Y. L. Nascent Focal Adhesions Are Responsible for the Generation of Strong Propulsive Forces in Migrating Fibroblasts J. Cell Biol. 2001, 153, 881-888
40. Dao, P.; Garbay, C.; Chen, H. High Yielding Microwave-Assisted Synthesis of Tri-Substituted 1,3,5-Triazines Using Pd-Catalyzed Aryl and Heteroarylamination Tetrahedron 2012, 68, 3856-3860
41. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility J. Comput. Chem. 2009, 30, 2785-2791